Kelyniam Global Announces Q2 2025 Financial Results
Kelyniam Global (OTC: KLYG), a manufacturer of custom cranial and craniofacial implants, reported challenging Q2 2025 financial results. The company experienced a 20.2% decrease in revenue to $1,364,432 compared to Q2 2024, with gross margin declining 18.1% to $1,090,691.
The company shifted from an operating profit of $172,093 in Q2 2024 to an operating loss of $59,869 in Q2 2025. Despite these challenges, management highlighted improved Q2 performance compared to Q1, attributing slower periods to the unpredictable nature of the cranial implant market. The company maintains its competitive advantage through 24-48 hour delivery of custom implants for rush cases.
Kelyniam Global (OTC: KLYG), produttore di impianti cranici e craniofacciali su misura, ha riportato risultati finanziari difficili nel secondo trimestre 2025. L'azienda ha registrato una riduzione dei ricavi del 20.2% a $1,364,432 rispetto al Q2 2024, con un margine lordo in calo del 18.1% a $1,090,691.
La società è passata da un utile operativo di $172,093 nel Q2 2024 a una perdita operativa di $59,869 nel Q2 2025. Nonostante queste difficoltà, la direzione ha sottolineato un miglioramento delle performance nel Q2 rispetto al Q1, attribuendo i periodi più lenti alla natura imprevedibile del mercato degli impianti cranici. L'azienda mantiene il suo vantaggio competitivo grazie alla consegna in 24-48 ore di impianti su misura per i casi urgenti.
Kelyniam Global (OTC: KLYG), fabricante de implantes craneales y craneofaciales personalizados, informó resultados financieros difíciles en el segundo trimestre de 2025. La compañía experimentó una caída del 20.2% en los ingresos a $1,364,432 respecto al Q2 de 2024, con el margen bruto disminuyendo un 18.1% hasta $1,090,691.
La empresa pasó de un beneficio operativo de $172,093 en el Q2 de 2024 a una pérdida operativa de $59,869 en el Q2 de 2025. A pesar de estos retos, la dirección destacó una mejora en el rendimiento en el Q2 frente al Q1, atribuyendo los periodos de menor actividad a la naturaleza impredecible del mercado de implantes craneales. La compañía mantiene su ventaja competitiva gracias a la entrega en 24-48 horas de implantes personalizados en casos urgentes.
Kelyniam Global (OTC: KLYG)는 맞춤형 두개골 및 두개안면 임플란트를 제조하는 회사로, 2025년 2분기에 어려운 재무 실적을 보고했습니다. 회사는 전년 동기(Q2 2024) 대비 매출이 20.2% 감소하여 $1,364,432를 기록했으며, 총이익은 18.1% 감소한 $1,090,691였습니다.
회사는 2024년 2분기 영업이익 $172,093에서 2025년 2분기에는 영업손실 $59,869로 전환했습니다. 이러한 어려움에도 불구하고 경영진은 1분기 대비 2분기 실적이 개선되었다고 강조했으며, 부진한 시기는 두개골 임플란트 시장의 예측 불가능성 때문이라고 설명했습니다. 회사는 긴급 사례에 대해 맞춤형 임플란트를 24~48시간 내에 배송함으로써 경쟁 우위를 유지하고 있습니다.
Kelyniam Global (OTC: KLYG), fabricant d'implants crâniens et craniofaciaux sur mesure, a publié des résultats financiers difficiles pour le deuxième trimestre 2025. La société a enregistré une baisse de 20,2 % de son chiffre d'affaires à 1,364,432 $ par rapport au T2 2024, avec une marge brute en recul de 18,1 % à 1,090,691 $.
La société est passée d'un résultat d'exploitation de 172,093 $ au T2 2024 à une perte d'exploitation de 59,869 $ au T2 2025. Malgré ces difficultés, la direction a souligné une amélioration des performances au T2 par rapport au T1, attribuant les périodes plus calmes à la nature imprévisible du marché des implants crâniens. L'entreprise conserve son avantage concurrentiel grâce à la livraison sous 24 à 48 heures d'implants sur mesure pour les cas urgents.
Kelyniam Global (OTC: KLYG), ein Hersteller von kundenspezifischen Schädel- und kraniofazialen Implantaten, meldete schwierige Finanzergebnisse für das zweite Quartal 2025. Das Unternehmen verzeichnete einen Umsatzrückgang von 20,2% auf $1,364,432 im Vergleich zum zweiten Quartal 2024, wobei die Bruttomarge um 18,1% auf $1,090,691 sank.
Das Unternehmen wechselte von einem Betriebsgewinn von $172,093 im Q2 2024 zu einem Betriebsverlust von $59,869 im Q2 2025. Trotz dieser Herausforderungen hob das Management eine Verbesserung der Performance im Q2 gegenüber dem Q1 hervor und führte ruhigere Phasen auf die unvorhersehbare Natur des Marktes für Schädelimplantate zurück. Das Unternehmen behält seinen Wettbewerbsvorteil durch die 24–48-stündige Lieferung maßgefertigter Implantate für Eilfälle.
- Improved quarter-over-quarter performance from Q1 to Q2 2025
- Maintained strong 24-48 hour delivery capability for rush cases
- Record levels of shareholder participation in annual meeting
- Revenue decreased 20.2% year-over-year to $1.36M in Q2 2025
- Gross margin declined 18.1% compared to Q2 2024
- Shifted from operating profit to loss of $59,869
"The Company made up significant ground from the difficult comparisons in the first quarter," said Ross Bjella, CEO of Kelyniam. "Kelyniam focused its efforts on sales execution and the 2nd quarter on quarter results improved nicely over Q1 performance. The cranial implant market is driven by unforeseeable events and some time periods are busier than others. Q1 this year was just a slower period and our distributors worked hard to capture as many available opportunities as possible in Q2."
Q2 2025 Financial Highlights (compared to Q2 2024):
- Total revenue of
$1,364,432 $1,709,239 20.2% . - Gross margin of
$1,090,691 $1,330,965 18.1% . - Operating loss of
$(59.86 9)$172,093
Desiree Webb, Kelyniam's Chief Operating and Revenue Officer said, "Kelyniam's unique advantage of delivering complex custom cranial and craniofacial implants within 24-48 hours for rush and expedited cases allows us to pivot quickly for surgeons, sales reps and distributors. The Company experienced greater sales over the prior year in the latter part of Q2 in part to a laser focus on sales as we head into the trauma season."
The Company held its annual shareholder meeting on June 23rd and all matters of official business passed with record levels of participation.
Kelyniam's complete financial results are available at www.kelyniam.com.
About Kelyniam Global, Inc.
Kelyniam Global, Inc. designs, manufactures, and distributes custom cranial and craniofacial implants using biocompatible materials. Known for its rapid 24-48 hour delivery, Kelyniam collaborates with surgeons and healthcare providers to improve clinical outcomes. Learn more at www.kelyniam.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including those regarding future sales, distributor expansion, and the impact of strategic partnerships, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include economic conditions, competitive pressures, regulatory changes, and challenges in executing sales strategies, as detailed in Kelyniam's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Kelyniam undertakes no obligation to update these statements except as required by law.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-announces-q2-2025-financial-results-302526567.html
SOURCE Kelyniam Global Inc
FAQ
What were Kelyniam Global's (KLYG) Q2 2025 earnings results?
How much did Kelyniam's (KLYG) gross margin decline in Q2 2025?
What is Kelyniam's competitive advantage in the cranial implant market?
Why did Kelyniam (KLYG) experience lower sales in Q2 2025?
How did Kelyniam perform in Q2 2025 compared to Q1 2025?
